Vilaprisan (BAY1002670)
Sponsors
Bayer
Conditions
Clinical Trial, Phase IEndometriosisLeiomyomaUterine FibroidsUterine Fibroids and Heavy Menstrual Bleeding
Phase 1
Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan
CompletedNCT02262663
Start: 2014-10-31End: 2015-12-31Updated: 2016-03-16
Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan
CompletedNCT02456129
Start: 2015-07-31End: 2016-02-29Updated: 2016-03-02
Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)
CompletedNCT03092999
Start: 2017-03-28End: 2017-07-17Updated: 2017-08-18
Pharmacokinetics and Safety of Vilaprisan in Renal Impairment
CompletedNCT03411980
Start: 2018-02-02End: 2019-02-06Updated: 2019-12-03
Phase 2
Phase 3
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
TerminatedNCT03194646
Start: 2017-06-30End: 2024-07-11Updated: 2025-07-28
A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
TerminatedNCT03240523
Start: 2017-07-31End: 2021-10-25Updated: 2024-10-18
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)
TerminatedNCT03400943
Start: 2018-01-17End: 2022-04-06Updated: 2023-05-03
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)
TerminatedNCT03400956
Start: 2018-01-24End: 2021-06-30Updated: 2022-06-30
A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding
TerminatedNCT03476928
Start: 2018-03-30End: 2021-07-12Updated: 2022-07-08
Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
WithdrawnNCT03699176
Start: 2018-10-27End: 2019-12-25Updated: 2020-01-18